Literature DB >> 16606360

Neprilysin activity and expression are controlled by nicastrin.

R Pardossi-Piquard1, J Dunys, G Yu, P St George-Hyslop, C Alves da Costa, F Checler.   

Abstract

We recently demonstrated that the presenilin-dependent gamma-secretase complex regulates the expression and activity of neprilysin, one of the main enzymes that degrade the amyloid beta-peptide (Abeta) which accumulates in Alzheimer's disease. Here, we examined the influence of endogenous nicastrin (NCT), a member of the gamma-secretase complex, on neprilysin physiology. We show that nicastrin deficiency drastically lowers neprilysin expression, membrane-bound activity and mRNA levels, but it did not modulate the expression of two other putative Abeta-cleaving enzymes, endothelin-converting enzyme and insulin-degrading enzyme. Furthermore, we show that nicastrin restores neprilysin activity and expression in nicastrin-deficient, but not presenilin-deficient fibroblasts, indicating that the control of neprilysin necessitates the complete gamma-secretase complex harbouring its four reported components. Finally, we show that NCT expression peaked 24 h after NCT cDNA transfection of wild-type and NCT-/- fibroblasts, while neprilysin expression drastically increased only after 36 h and was maximal at 48 h. This delayed effect on neprilysin expression correlates well with our demonstration of an indirect gamma-secretase-dependent modulation of neprilysin at its transcriptional level.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16606360     DOI: 10.1111/j.1471-4159.2006.03822.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

1.  Gleevec increases levels of the amyloid precursor protein intracellular domain and of the amyloid-beta degrading enzyme neprilysin.

Authors:  Yvonne S Eisele; Matthias Baumann; Bert Klebl; Christina Nordhammer; Mathias Jucker; Ellen Kilger
Journal:  Mol Biol Cell       Date:  2007-07-11       Impact factor: 4.138

Review 2.  Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?

Authors:  Andrew F Teich; Ottavio Arancio
Journal:  Biochem J       Date:  2012-09-01       Impact factor: 3.857

3.  A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete loss of gamma-secretase activity.

Authors:  Elizabeth A Heilig; Weiming Xia; Jie Shen; Raymond J Kelleher
Journal:  J Biol Chem       Date:  2010-05-11       Impact factor: 5.157

4.  Mechanisms of enzymatic degradation of amyloid Beta microfibrils generating nanofilaments and nanospheres related to cytotoxicity.

Authors:  Keiji Numata; David L Kaplan
Journal:  Biochemistry       Date:  2010-04-20       Impact factor: 3.162

5.  Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.

Authors:  Mohamed Lotfy; Jaipaul Singh; Huba Kalász; Kornelia Tekes; Ernest Adeghate
Journal:  Open Med Chem J       Date:  2011-09-09

6.  The amyloid precursor protein intracellular domain-fe65 multiprotein complexes: a challenge to the amyloid hypothesis for Alzheimer's disease?

Authors:  Daniel A Bórquez; Christian González-Billault
Journal:  Int J Alzheimers Dis       Date:  2012-02-09

Review 7.  Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer's Disease.

Authors:  Marcus O W Grimm; Janine Mett; Christoph P Stahlmann; Viola J Haupenthal; Valerie C Zimmer; Tobias Hartmann
Journal:  Front Aging Neurosci       Date:  2013-12-23       Impact factor: 5.750

Review 8.  New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection.

Authors:  A J Turner; N N Nalivaeva
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

9.  TMP21 transmembrane domain regulates gamma-secretase cleavage.

Authors:  Raphaëlle Pardossi-Piquard; Christopher Böhm; Fusheng Chen; Soshi Kanemoto; Frédéric Checler; Gerold Schmitt-Ulms; Peter St George-Hyslop; Paul E Fraser
Journal:  J Biol Chem       Date:  2009-08-25       Impact factor: 5.157

10.  SUMO1 impact on Alzheimer disease pathology in an amyloid-depositing mouse model.

Authors:  Erin Knock; Shinsuke Matsuzaki; Hironori Takamura; Kanayo Satoh; Grace Rooke; Kyung Han; Hong Zhang; Agnieszka Staniszewski; Taiichi Katayama; Ottavio Arancio; Paul E Fraser
Journal:  Neurobiol Dis       Date:  2017-12-05       Impact factor: 7.046

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.